Prevagen Research Papers

Alzheimer's Disease is a condition that affects 50% of the population over the age of eighty five, which equals four million Americans each year. It is becoming an important and high-profile issue in today's society for everyone. There are rapid advancements being made in the fight against this disease now more than ever, and the purpose of this essay is to educate the public on the background as well as the new discoveries. There are many new drugs that are being tested and studied every day which slow down, and may even halt the progress of the disease.

In times past many people thought that memory loss was a normal occurrence for elderly people. This thinking was major reason for why Alzheimer’s disease was not caught until very later in the stages. Alzheimer’s disease is not a normal part of aging. After heart disease, cancer, and strokes, Alzheimer’s is the most common cause of death in adults in the Western world. “It is estimated that 4.5 million Americans over the age of 65 are affected with this condition. After the age of 65, the incidence of the disease doubles every five years and, by age 85, it will affect nearly half of the population” (Robinson).

This study will investigate and test how some medications can smooth the progressive advance of the Alzheimer in patients with more than 70 years. Alzheimer which is a degenerative disease of the neuro system due to memory loss is still being very questionable and debated. As of today there is no cure, nor reversal for the disease. Many researchers are still studding and looking for therapies and medication that can stop or reverse the development of the disease. It is very important to prove that some medications can help to cope with the disease. In my study I will be able to demonstrate

so I was curious about this pill that claimed it could support memory and improve brain function the pill is called "Prevagen" and makes many claims about what it can do. this was one of the articals I read about this so called "magical pill."

Throughout history there have been reports of decreased memory and mental deterioration that accompanied old age. Alzheimer’s disease (AD) was named after Dr. Alois Alzheimer who described the symptoms in a woman in Germany in the 1907 but it was not until the 1970’s that AD was considered to be a major disorder and AD continues to be a major health concern worldwide (Reger, 2002).

Inclusion criteria would include standard Alzheimer’s medications, as long as they have been used for two or more months6. This is to control the possibility of a different possible experimental medication being used at the same time as this study. Exclusion criteria would include other cognitive illnesses that impair memory, as well as cancer6. It is best to have patients with only one memory-impairing disease to be sure any positive or negative correlations are limited to the disease of interest. The exclusion would also include participants who have higher than normal levels of lipoprotein lipase6,9.

Ritalin, and Adderall, respectively. Although originally developed to treat diagnosed conditions ranging from narcolepsy to attention deficit hyperactivity disorder, their off-label use has been reported to increase users’ recall, attention span, and ability to focus on cognitive tasks; in addition, modafinil has been shown to increase wakefulness (Butcher 2003; greely et al. 2008). Some CEDs also seem to enhance users’ “executive function,” or problem-solving ability (Mehlman 2004, p. 484). Beyond the currently available drugs, research into Alzheimer’s disease and other causes of cognitive decline in the elderly is likely to contribute, intentionally or not, to the further

Scientists may have discovered a drug that can help patients with Alzheimer's disease. The drug named solanezumab can slow down the rate of memory loss in patients suffering from mild Alzheimer's.

There is a need for future research that focuses on effective PM strategies that are applicable in everyday living for older adults. Formation of more strategies that combine efforts to improve memory at both encoding and retrieval, and tap into the benefits available

Memory span is a measure of short term memory and its capacity through the use of a list. Participants are asked to review a list of items, retain, and immediately recall as accurate as possible. The list may be conducted with a random list of numbers, words, or letters since these items may influence differently amongst each participant. The list is also varied in item length to test in which particular length the participant is subject to make the least of errors and determine their memory span. The average short-term memory capacity is ranged

The experiment was conducted within a year, which involved one hundred and twenty patients within the ages of fifty and above. These participants showed signs of acquiring Alzheimer’s disease due to the fact that they experienced a minor condition of dementia. The experiment was led in a double blind manner where both the subjects and researchers do not know which type of treatment the participants received. The participants were divided into two groups, an experimental group and a control group. The experimental group received the capsule

Dementia, defined by the Alzheimer’s Association, is the overall term for diseases and conditions characterized by a decline in memory or other thinking skills that affects a person’s ability to perform everyday activities. More than 250,000 Americans will develop dementia (including Alzheimer 's) when they are sixty-five or older and at eighty-five the risk of developing Alzheimer’s is fifty percent. Since this disease was found in 1907 by Alois Alzheimer, there have been thousands of dollars, research, and clinical trials put into finding a cure for this horrible disease. This literature review examines the effects of the type of Dementia known as

Dementia is one of the age-related disorders which commonly affect the aging elderly population (65 and over). In 2010, the approximate number of people who had dementia was 35.6 million and it is estimated to double every twenty years, to 65.7 million in 2030 and 115.4 million in 2050 respectively. The incidence of dementia every year is 7.7 million which equals to one new case every four seconds (World Health Organization [WHO], 2012). In 2011, the Canadian baby boom generation initially began to turn 65 and became part of the elderly population which significantly impacted the fertility rates (Rockwood & Keren, 2010). In Canada, the elderly population accounts for approximately 13% of the population and one in eleven has dementia (Stein-Parbury & Eliopoulos, 2014). The researchers have estimated that by 2036, it will account for 25% of the population and 28% by 2061 (Bartfay, Bartfay & Gorey, 2013). There are many forms of dementia that an individual can acquire. Alzheimer’s disease is one of the common forms of dementia in the elderly population (National Institutes of Health, 2013). Currently, approximately five million Americans have Alzheimer’s disease (WHO, 2012) from which two thirds account for women (Alzheimer’s Association, 2014). The reason behind more women having Alzheimer’s disease is merely due to the fact that women have higher life expectancy and old age contributes to higher risk for acquiring Alzheimer’s disease. It is apparent that Alzheimer’s disease

Alzheimer Disease, the most common form of dementia (to a group of symptoms affecting the brain), is a neurological disorder affecting an individual’s memory, thinking skills, and ability to conduct simply everyday tasks. Alzheimer Disease is irreversible, and no cure has been established. Dr. Alois Alzheimer-the individual in which the disease is named after-detected Alzheimer in 1906 from a woman with abnormal clumps and tangled neurofibrillary (Castellani 2010). These characteristics of the brain are now directly associated with Alzheimer Disease. There are essentially two forms of the disease. Both experience the same symptoms, but one is early onset and the second is late onset. In early onset Alzheimer Disease, symptoms develop as early as 30 years of age. Late onset AD, the most common form, develops at sixty years of age and older. A family history of the disease does improve the individual’s probability of experiencing symptoms. The progression of this paper will consist of the medical changes caused by Alzheimer, how an individual can obtain it, and lastly prevention methods discovered throughout the years.

The experimental group was those who have Alzheimer’s disease and the control was without one.